Kane Biotech Stock Key Fundamental Indicators
| KNBIF Stock | USD 0.03 0 6.96% |
As of the 2nd of February, Kane Biotech secures the Mean Deviation of 2.36, downside deviation of 11.98, and Risk Adjusted Performance of 0.0319. Kane Biotech technical analysis lets you operate historical price patterns with an objective to determine a pattern that forecasts the direction of the firm's future prices. Please verify Kane Biotech jensen alpha and the relationship between the value at risk and kurtosis to decide if Kane Biotech is priced some-what accurately, providing market reflects its recent price of 0.0294 per share. As Kane Biotech appears to be a penny stock we also strongly suggest to check its total risk alpha numbers.
Kane Biotech's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Kane Biotech's valuation are provided below:Kane Biotech does not presently have any fundamental ratios for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Kane |
Kane Biotech 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Kane Biotech's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Kane Biotech.
| 11/04/2025 |
| 02/02/2026 |
If you would invest 0.00 in Kane Biotech on November 4, 2025 and sell it all today you would earn a total of 0.00 from holding Kane Biotech or generate 0.0% return on investment in Kane Biotech over 90 days. Kane Biotech is related to or competes with Biovaxys Technology. Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies ... More
Kane Biotech Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Kane Biotech's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Kane Biotech upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 11.98 | |||
| Information Ratio | 0.024 | |||
| Maximum Drawdown | 27.72 | |||
| Value At Risk | (5.78) | |||
| Potential Upside | 8.2 |
Kane Biotech Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Kane Biotech's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Kane Biotech's standard deviation. In reality, there are many statistical measures that can use Kane Biotech historical prices to predict the future Kane Biotech's volatility.| Risk Adjusted Performance | 0.0319 | |||
| Jensen Alpha | 0.141 | |||
| Total Risk Alpha | (0.10) | |||
| Sortino Ratio | 0.0111 | |||
| Treynor Ratio | 0.2144 |
Kane Biotech February 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0319 | |||
| Market Risk Adjusted Performance | 0.2244 | |||
| Mean Deviation | 2.36 | |||
| Semi Deviation | 4.18 | |||
| Downside Deviation | 11.98 | |||
| Coefficient Of Variation | 3115.92 | |||
| Standard Deviation | 5.56 | |||
| Variance | 30.94 | |||
| Information Ratio | 0.024 | |||
| Jensen Alpha | 0.141 | |||
| Total Risk Alpha | (0.10) | |||
| Sortino Ratio | 0.0111 | |||
| Treynor Ratio | 0.2144 | |||
| Maximum Drawdown | 27.72 | |||
| Value At Risk | (5.78) | |||
| Potential Upside | 8.2 | |||
| Downside Variance | 143.58 | |||
| Semi Variance | 17.45 | |||
| Expected Short fall | (9.90) | |||
| Skewness | (0.51) | |||
| Kurtosis | 9.55 |
Kane Biotech Backtested Returns
Kane Biotech appears to be out of control, given 3 months investment horizon. Kane Biotech has Sharpe Ratio of 0.12, which conveys that the firm had a 0.12 % return per unit of risk over the last 3 months. By analyzing Kane Biotech's technical indicators, you can evaluate if the expected return of 0.59% is justified by implied risk. Please exercise Kane Biotech's Downside Deviation of 11.98, risk adjusted performance of 0.0319, and Mean Deviation of 2.36 to check out if our risk estimates are consistent with your expectations. On a scale of 0 to 100, Kane Biotech holds a performance score of 9. The company secures a Beta (Market Risk) of 0.79, which conveys possible diversification benefits within a given portfolio. As returns on the market increase, Kane Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Kane Biotech is expected to be smaller as well. Please check Kane Biotech's sortino ratio, semi variance, rate of daily change, as well as the relationship between the value at risk and kurtosis , to make a quick decision on whether Kane Biotech's current price movements will revert.
Auto-correlation | 0.35 |
Below average predictability
Kane Biotech has below average predictability. Overlapping area represents the amount of predictability between Kane Biotech time series from 4th of November 2025 to 19th of December 2025 and 19th of December 2025 to 2nd of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Kane Biotech price movement. The serial correlation of 0.35 indicates that nearly 35.0% of current Kane Biotech price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.35 | |
| Spearman Rank Test | 0.52 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Based on the latest financial disclosure, Kane Biotech has a Return On Asset of -0.3915. This is 95.53% lower than that of the Healthcare sector and 98.34% lower than that of the Biotechnology industry. The return on asset for all United States stocks is 179.64% higher than that of the company.
Kane Biotech Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kane Biotech's current stock value. Our valuation model uses many indicators to compare Kane Biotech value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kane Biotech competition to find correlations between indicators driving Kane Biotech's intrinsic value. More Info.Kane Biotech is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kane Biotech's earnings, one of the primary drivers of an investment's value.Kane Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kane Biotech's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Kane Biotech could also be used in its relative valuation, which is a method of valuing Kane Biotech by comparing valuation metrics of similar companies.Kane Biotech is currently under evaluation in return on asset category among its peers.
Kane Fundamentals
| Return On Equity | -5.97 | |||
| Return On Asset | -0.39 | |||
| Profit Margin | (1.80) % | |||
| Operating Margin | (1.72) % | |||
| Current Valuation | 12.47 M | |||
| Shares Outstanding | 124.83 M | |||
| Shares Owned By Insiders | 26.82 % | |||
| Price To Earning | 4.68 X | |||
| Price To Book | 102.61 X | |||
| Price To Sales | 3.45 X | |||
| Revenue | 1.61 M | |||
| Gross Profit | 568.44 K | |||
| EBITDA | (4.25 M) | |||
| Net Income | (4.6 M) | |||
| Cash And Equivalents | 2.53 M | |||
| Cash Per Share | 0.02 X | |||
| Total Debt | 1.12 M | |||
| Debt To Equity | 7.12 % | |||
| Current Ratio | 0.67 X | |||
| Book Value Per Share | (0.05) X | |||
| Cash Flow From Operations | (2.29 M) | |||
| Earnings Per Share | (0.03) X | |||
| Number Of Employees | 18 | |||
| Beta | 0.19 | |||
| Market Capitalization | 10.45 M | |||
| Total Asset | 6.13 M | |||
| Z Score | 5.4 | |||
| Net Asset | 6.13 M |
About Kane Biotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kane Biotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kane Biotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kane Biotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Kane Biotech Inc., a biotechnology company, engages in the research, development, and commercialization of technologies and products that prevent and remove microbial biofilms in Canada and internationally. Kane Biotech Inc. was incorporated in 2001 and is based in Winnipeg, Canada. Kane Biotech is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
| VGIAX | Vanguard Growth And | |
| XAR | SPDR SP Aerospace | |
| XAR | SPDR SP Aerospace | |
| XAR | SPDR SP Aerospace | |
| ASML | ASML Holding NV |
Other Information on Investing in Kane Pink Sheet
Kane Biotech financial ratios help investors to determine whether Kane Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kane with respect to the benefits of owning Kane Biotech security.